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Abstract 27 
Objectives 28 
This study aimed to evaluate the acceptance of home blood glucose monitoring (HBGM) by owners of 29 
recently diagnosed diabetic cats, and the impact of choosing HBGM on the quality of life (QoL) changes of cat 30 
and owner, in addition to glycaemic changes during 6 months’ follow-up. 31 
Methods 32 
Owners of cats diagnosed with diabetes mellitus (DM) and treated with insulin for 6-20 weeks were divided 33 
into a HBGM group and a non-HBGM group based on their ability and willingness to perform HBGM after 34 
standardised instruction session. The HBGM acceptance level and reasons for acceptance failure were 35 
documented; a questionnaire evaluated owners’ experiences. For the following 6 months, changes in QoL, 36 
measured using the validated DIAQoL-pet quantification tool, and changes in glycaemic control parameters 37 
(clinical signs, serum fructosamine, blood glucose curve average/minimal/maximal/pre-insulin blood glucose 38 
[BG]) were compared between HBGM and non-HBGM groups at months 1, 3 and 6, as well as within the 39 
groups between baseline and months 1, 3 and 6.  40 
Results 41 
Thirty-eight cats were enrolled; 28 (74%) entered the HBGM group. There was no significant difference 42 
between groups in overall DIAQoL-pet score or glycaemic control parameters at any time point apart from the 43 
maximal BG at month 6 (lower in the HBGM group). However, the DIAQoL-pet score, including indicators of 44 
owner worry about DM, worry about hypoglycaemia and costs, as well as glycaemic parameters, improved at 45 
all time-points within the HBGM group, but not within the non-HBGM group. Remission occurred in 9/28 (32%) 46 
HBGM group cats and 1/10 (10%) non-HBGM group cats (p=0.236). 47 
Conclusions and Relevance 48 
HBGM was adopted successfully by most diabetic cat owners. Despite the extra task, positive changes in 49 
QoL-parameters occurred in the HBGM group and not in the non-HBGM group. Although no difference was 50 
found in glycaemic control between HBGM and non-HBGM group during the 6 months’ follow-up, significant 51 
glycaemic improvements were documented in the HBGM group. 52 
  53 
Introduction 54 
The management of feline diabetes mellitus (DM) is complex and is facilitated by cat owners understanding 55 
the disease and their active participation in treatment. These factors help achieve the main treatment goals, 56 
which include resolution of clinical signs and avoidance of hypoglycaemia and diabetic complications.1,2 57 
However, the daily involvement in the management of their pets’ diabetes can also be perceived as a 58 
substantial burden by some owners.3,4 A tool called DIAQoL-pet has been developed and psychometrically 59 
validated to qualify and quantify the quality of life (QoL) of diabetic pets and their owners, allowing more 60 
specific monitoring of this important aspect of feline diabetes, alongside more traditional glycaemic 61 
parameters.3,4  62 
Although not considered a main treatment goal,1,2 some diabetic cats enter diabetic remission. The highest 63 
remission rates have been reported in cats where good glycaemic control has been established early in the 64 
course of the disease.5,6 The role of home blood glucose monitoring (HBGM) in achieving early good 65 
glycaemic control has been widely acknowledged and has been included in the latest guidelines for 66 
management of DM in cats.2 In human medicine, self-monitoring of blood glucose (SMBG) has been an 67 
integral part of management of humans with type 1 and insulin-treated type 2 diabetes for many decades.7 68 
However, although the recommendations for treatment of human diabetes emphasise the utility of SMBG to  69 
assess individual responses to therapy and prevention of hypoglycaemia, concerns about the potential 70 
impacts of SMBG on QoL, particularly in people with type 2 DM, have been raised.8,9 In veterinary medicine, 71 
the difficulties pet owners might encounter and the reasons for reluctance to perform HBGM have been 72 
sporadically addressed in previous canine and feline studies.10-13 However, these reports were mostly 73 
concerned with biological effects as outcome parameters and merely listed what owners perceived as 74 
challenges and benefits of HBGM. A prospective assessment of the possible psychosocial impact of HBGM, 75 
using an objective validated measure such as the DIAQoL-pet, in a substantial number of patients with a 76 
longer-term follow-up is yet to be reported in veterinary medicine. 77 
The main aim of this study was therefore to evaluate the acceptance of HBGM by cat owners and its impact 78 
on QoL changes in diabetic cats and their owners over a 6-month period using the previously validated QoL 79 
tool, DIAQoL-pet.3 A secondary aim was to assess the effect of HBGM on glycaemic changes over the same 80 
time period. 81 
 82 
Materials and methods 83 
Cats diagnosed with DM ≤5 months previously and treated with insulin for at least 6 weeks prior to enrolment 84 
were recruited for the study between October 2013 and September 2015. The study was approved by the 85 
institutional Clinical Research and Ethical Review Board and was performed under Home Office Licence no. 86 
70/7393. The diagnosis of DM was made based on a combination of appropriate clinical signs (polyuria, 87 
polydipsia, polyphagia, weight loss) and laboratory parameters (hyperglycaemia [blood glucose (BG) >15 88 
mmol/L], glycosuria). Cats were excluded if they received short-acting systemic glucocorticoids in the previous 89 
month, depot glucocorticoids in the previous 2 months or progestogens in the previous 6 months. Cats were 90 
also excluded if they were diagnosed with diabetic ketoacidosis at initial evaluation, if they were diagnosed 91 
and treated for hyperthyroidism (except for cats successfully treated with radioactive iodine or thyroidectomy) 92 
or were diagnosed with severe disease that could increase the risk associated with study participation or 93 
require long-term medication. All cats were screened for hypersomatotropism and if found positive (based on 94 
insulin-like growth factor 1 [IGF-1]>1000 ng/mL)14 were not included. 95 
On initial presentation, a thorough history was taken and physical examination, including body weight (BW), 96 
estimation of body condition score (BCS; 1-9/9)15 and percentage of body fat (% of BF)16, were performed. 97 
The severity of each cat’s clinical signs at trial recruitment was graded using the validated clinical scoring 98 
system (Diabetic Clinical Score) shown in Table 1.17 Cat owners were also asked to complete the DIAQoL-pet 99 
survey to assess the influence of DM and its treatment on QoL.3 The DIAQoL-pet generated an Average-100 
Weighted Impact Score (AWIS) to reflect pet and owner QoL, with more negative values reflecting a more 101 
negative impact of DM.3,4 102 
All cats underwent initial screening tests including complete blood count (CBC), plasma biochemistry, full 103 
urinalysis (including urine culture), and serum fructosamine, total T4 (TT4), feline pancreatic lipase 104 
immunoreactivity (fPLI), IGF-1 measurement, and abdominal ultrasound. A 24-hour blood glucose curve 105 
(BGC) was performed on each cat after admission, using either a continuous glucose monitoring system for 106 
the measurement of glucose in the subcutaneous interstitial fluid (Guardian REAL-Time system, Medtronic) or 107 
serial BG measurements in capillary blood collected from the ear using a portable BG meter (AlphaTRAK® 2, 108 
Zoetis). In the latter case, BG was measured every 2 hours or more frequently if hypoglycaemia (BG<3 109 
mmol/L) occurred. All cats were then transitioned onto a longer-acting insulin type (recombinant human 110 
protamine zinc insulin [PZIR; ProZinc, Boehringer Ingelheim] or synthetic insulin analogue glargine [Lantus, 111 
Sanofi]) at an initial dose of 0.2-0.7 U/kg. Cats were fed a low carbohydrate, high protein diet (Purina Pro Plan 112 
DM, Nestle Purina PetCare; wet or dry, depending on cat’s preference), which commenced at least 10 days 113 
prior to the enrolment visit.  114 
At discharge from the hospital, all cats received comprehensive introduction to HBGM which took at least 30 115 
minutes. Owners were shown how to obtain a blood drop using the marginal ear vein technique and they 116 
practised the technique on their own cat with the clinician. Cat owners were also taught how to use the 117 
glucometer for measurement and how to calibrate it. To generate data for a BGC, owners were asked to 118 
measure BG every 2 hours over a 12-hours period, starting just before morning feeding and insulin injection, 119 
and finishing just before evening feeding and insulin injection. Owners were asked to record the data and 120 
send the results to the research clinic and describe any clinical signs of diabetes that occurred around the 121 
time of the BGC. Owners were asked to perform a BCG at the 1-week and 2-, 4- and 5-month trial time-points, 122 
and also 1-2 weeks after any insulin dose adjustments. If owners did not perform HBGM, it was requested that 123 
these BGCs were performed at the cat’s primary-care practice. Cats that entered diabetic remission were 124 
initially monitored using spot blood glucose checks 2-4 times weekly, but spot blood glucose measurements 125 
were not otherwise routinely requested for monitoring. 126 
Re-examinations at the research clinic were performed 2 weeks, 1 month, 3 and 6 months after joining the 127 
trial. At these time points, a full history and physical examination, serum fructosamine measurement, diabetic 128 
clinical score (DCS), and a 24-hour BGC were performed in all cats. Owners were also asked to complete the 129 
DIAQoL-pet survey. Additional monthly to bimonthly re-examinations took place at the referring veterinary 130 
practices, depending on the needs of individual cats. During the study, insulin dose was adjusted according to 131 
a single, nadir-led protocol, based on BGC results.17 Diabetic remission was defined as not requiring insulin 132 
for more than 4 weeks. 133 
Owners were considered to have successfully adopted HBGM (“HBGM group”) if they had performed a 134 
minimum of 2 BGCs at home within the first 3 months of enrolment.  The remaining owners and their cats 135 
were included in the “non-HBGM group”. This arbitrary cut-off of 2 BGCs was chosen, since the investigators 136 
explicitly did not want to include owners into the HBGM group if they had successfully performed one curve, 137 
though decided against further testing as a result of this experience. 138 
At the end of the study period, owners were contacted by email and/or telephone and asked to complete a 139 
questionnaire to describe their experiences with HBGM. The owners of cats included in the HBGM group were 140 
asked about their general opinions of HBGM (e.g. if their lives were restricted by HBGM; 141 
advantages/disadvantages of HBGM), the technique used for generating the BGCs, and difficulties they 142 
encountered during HBGM (Supplement 1). The owners of cats in the non-HBGM group were asked why they 143 
decided not to perform HBGM, or, if they performed some monitoring but then discontinued, why they 144 
discontinued (Supplement 2).  145 
 146 
Statistical analysis 147 
The data were tested for normality where appropriate (Shapiro-Wilks test). Signalment, BW, BCS, % of BF, 148 
fPLI, total number of BGCs performed during the study period, the time on insulin prior to enrolment, insulin 149 
type choice (PZIR vs. glargine) and the insulin dose at enrolment were compared between cats in the HBGM- 150 
and non-HBGM group using Mann-Whitney and Chi-Square tests, as appropriate. To evaluate the impact of 151 
HBGM on QoL changes in diabetic cats and owners, total DIAQoL-pet score and individual item-weighted 152 
impact scores (IWIS) for specific questions (Table 2) were compared between HBGM- and non-HBGM groups 153 
at enrolment and 1, 3 and 6 months after joining the trial. Similarly, DCS, twice-daily insulin dose and 154 
parameters of glycaemic control (serum fructosamine, average BG, average pre-insulin BG, minimal and 155 
maximal BG) were compared between the HBGM- and non-HBGM group at the same time points. Remission 156 
rate between groups (HBGM- vs. non-HBGM group) and the effect of the insulin type used (PZIR vs. glargine) 157 
on whether owners achieved HBGM, were compared using Chi-Square tests. 158 
DIAQoL-pet score, IWIS for specific questions (as above), DCS, insulin dose and parameters of glycaemic 159 
control (as above) were compared within each group to assess changes in QoL and glycaemic control over 160 
time. Wilcoxon Signed Ranks test were used to compare values at months 1, 3 and 6 to baseline (enrolment) 161 
values.  162 
Statistical analysis was performed using commercially available statistical software (SPSS version 22, IBM 163 
Statistics). 164 
 165 
Results 166 
Sixty-three cats were initially screened prior to enrolment in the 6-month trial and 46 cats were enrolled. 167 
Reasons for exclusion of the 17 cats were as follows: neoplastic disease/mass lesion (n=4); probable 168 
hypersomatotropism (on the basis of IGF-1>1000 ng/mL; n=3); excessively fearful or aggressive cats (n=3); 169 
cats already non-insulin dependent based on an in-hospital BGC (n=2); hyperthyroidism (n=1); 170 
gastrointestinal disease (n=1); clinical signs suggestive of a forebrain disease (n=1); hypertrophic 171 
cardiomyopathy with congestive heart failure (n=1); and cat owners declining study enrolment due to time 172 
constraints (n=1). 173 
Among the 46 cats enrolled in the 6-month trial, 8 were already performing HBGM, leaving 38 cats for study 174 
inclusion. Owners of 28 cats (74%) were able to perform HBGM (HBGM group). The remaining 10 cats (26%) 175 
were included in the non-HBGM group.  176 
There was no significant difference in the signalment, BW, BCS, % of BF, fPLI, time on insulin, insulin dose 177 
prior to enrolment, choice of insulin (PZIR vs glargine) between cats in the HBGM- and non-HBGM groups 178 
(Table 3). In the non-HBGM group, 90% cats (n=9) were male neutered compared to 46% (n=13) in the 179 
HBGM group (p=0.025).  180 
Cats in the HBGM group had a median of 5 (range 2-10) BGCs performed at home, while cats in the non-181 
HBGM had a median of 2.5 (range 1-7) BGCs performed at their primary veterinary practices during the 6-182 
months follow-up period. Each cat had additional 4 (range 2-4) BGCs performed at the research clinic during 183 
the same time period. The total number of BGCs (including curves performed at home, at the primary 184 
veterinary practices and at the research clinic) was not significantly different between the HBGM and non-185 
HBGM group (p=0.082). 186 
There was no difference between the HBGM- and non-HBGM group in regard to the total DIAQoL-pet score, 187 
scores for specific questions, DCS, insulin dose, or parameters of glycaemic control at any time point during 188 
the study, except for maximal BG at month 6, which was lower in the HBGM group (p=0.03; data shown in 189 
Supplement 3) (Figures 1-3, Table 3, Supplement 3). Total DIAQoL-pet score was significantly improved at 190 
months 1, 3 and 6 compared to baseline in the HBGM group but not in the non-HBGM group (Figure 1, Table 191 
4). There were significant decreases in scores (and therefore positive impact) for general worry about 192 
diabetes (“worry”; months 1, 3 and 6) and worry about hypoglycaemia in particular (“worry hypo”; months 3 193 
and 6), and worry about costs (months 3 and 6) in the HBGM group. There were also significant decreases in 194 
scores (indicating positive impact) for “restriction of owners’ activities” and “work restrictions” (month 6) in the 195 
HBGM group (Table 4). Overall, the scores for 6 of 9 specifically examined QoL areas had improved at month 196 
6 compared to baseline in the HBGM group (Table 4) but not in the non-HBGM group (Supplement 4). There 197 
were also significant reductions (i.e. improvements) in DCS, insulin dose and most parameters of glycaemic 198 
control (fructosamine, average BG, average pre-insulin BG, minimal/maximal BG) at months 1, 3 and 6 199 
compared to baseline in the HBGM group (Figures 2 and 3, Table 5), except for minimal BG at months 3 and 200 
6. In the non-HBGM group, DCS also decreased at months 1, 3 and 6 compared to baseline (p<0.05). 201 
Regarding insulin dose and parameters of glycaemic control in this group, only average pre-insulin BG at 202 
month 6 and maximal BG at month 1 were significantly different (lower; p<0.05) from baseline (Supplement 5). 203 
Diabetic remission occurred in 9/28 (32%) cats in the HBGM- and 1/10 (10%) cats in the non-HBGM group 204 
(p=0.236). 205 
Nineteen (68%) questionnaires were completed by owners of cats in the HBGM group. Ten of the 19 (53%) 206 
owners performed >10 BGCs and 17/19 (89%) found HBGM “straightforward” or “mostly straightforward” to 207 
perform; 2/19 (11%) respondents described it as “difficult”. Technical difficulties (pricking the ear, obtaining 208 
sufficient blood) were the most common challenges reported by 10/19 (53%) owners, followed by finding time 209 
to perform HBGM (n=6/19; 32%), and gaining confidence (n=5/19; 26%). Ten of the 19 (53%) respondents felt 210 
that their lives were not at all/not really restricted by HBGM, while 6/19 (32%) and 4/19 (21%) reported mild or 211 
moderate restriction, respectively. Most owners mentioned several advantages of HBGM; not having to take 212 
their cat to the veterinarian (n=16/19; 84%) or leave the cat at the practice (n=11/19; 58%) were the most 213 
commonly reported. A summary of the advantages and disadvantages of HBGM, and a description of the 214 
technique and difficulties encountered during HBGM, can be found in Table 6. Of cats in the HBGM group that 215 
were alive at the time of writing, all owners were still performing HBGM. 216 
Three of 10 questionnaires in the non-HBGM group were completed. Two owners managed to perform a few 217 
spot blood glucose measurements but not a whole curve; one owner tried performing curves but did not 218 
succeed. The reasons for discontinuing HBGM were stated as lack of assistance (n=2); a perception that the 219 
cat was anxious (n=3); difficulties obtaining a blood drop (n=2) or using a glucometer (n=2); and the 220 
perception that he/she was hurting the cat (n=1). Despite not being successful, one owner expressed a desire 221 
to try HBGM again, while the other two would “probably not”/”not” try it again.  222 
 223 
Discussion 224 
The main aim of this study was to determine the acceptance, and especially also the impact of HBGM on the 225 
QoL of diabetic cats and their owners. Although no significant difference in the overall QoL assessed by the 226 
DIAQoL-pet tool was found between the HBGM and non-HBGM group during the 6-months’ study period, the 227 
overall QoL scores improved at all post-enrolment time-points in the HBGM group and not in the non-HBGM 228 
group. This suggests a possible positive impact of HBGM. The acceptance of HBGM by the owners of 229 
diabetic cats was high, with approximately 3 out of 4 successfully adopting HBGM. This proportion is similar or 230 
higher than in previous studies evaluating HBGM in diabetic cats.11,12 Importantly, 89% of those performing 231 
HBGM found it “straightforward” or “mostly straightforward” and all questionnaire-respondents in the HBGM 232 
group would recommend HBGM to all or at least some owners of diabetic cats. Based on the questionnaire 233 
results, for owners practising HBGM, the benefits clearly outweighed any disadvantages. Notably, about half 234 
the owners in the HBGM group stated that they did not feel their lives were restricted by HBGM. This agreed 235 
with the results of the DIAQoL-pet assessment, indicating improvement of the overall QoL in the group 236 
performing HBGM. Further, owners practicing HBGM reported significantly less worry about their cat’s 237 
diabetes in general, and particularly about hypoglycaemia, compared to before the trial. This might be due to 238 
feeling more in control because of the ability to check blood glucose at home, as has been previously 239 
reported.11 The scores of specific questions about possible restriction of owners’ lives (“restrict your activities”, 240 
“social life”, “working life”) did not reveal negative effects associated with HBGM compared with the non-241 
HBGM group. The item “costs” also improved over time in the HBGM group, but not in the non-HBGM group, 242 
possibly reflecting cost savings because glycaemic checks were performed at home rather than at the 243 
veterinary clinic. 244 
The psychometrically validated DIAQoL-pet tool was used to objectively evaluate QoL in diabetic cats and 245 
their owners. Although other factors might have contributed to the score, successful adoption of HBGM was 246 
the major difference in the diabetes management after enrolment on the study. It is therefore likely that any 247 
negative impact HBGM might have had on the QoL would have been reflected in deterioration of the total 248 
DIAQoL-pet score or in the scores for the specific questions mentioned above. Since an improvement in 249 
DIAQoL-pet score occurred, HBGM was considered to most likely have a positive effect on QoL, rather than 250 
imposing an additional burden. In fact, HBGM group owners reported an improvement in impact on DIAQoL-251 
pet factors relating to life and work restrictions once the trial had started. This improvement was not 252 
documented in the non-HBGM group.  253 
Although improvement in QoL was documented in the HBGM group and not in the non-HBGM- group over 254 
time, the QoL scores were not different between these 2 groups at any time-point in the study. This lack of 255 
statistically significant difference might have several reasons. Firstly, the non-HBGM group was smaller than 256 
the HBGM group; secondly, the trial design resulted in cat owners essentially self-selecting group 257 
assignments; thirdly, the HBGM group was not absolutely homogenous in terms of the frequency and intensity 258 
of performing HBGM.  However, the total number of BGCs was not significantly different between the HBGM 259 
and non-HBGM group. Finally, lack of randomisation and owners’ self-assignment to the groups might allow 260 
for owner- or pet-related characteristics, intrinsic to the decision to accept or decline HBGM, to confound 261 
treatment outcomes. For instance, if HBGM group owners were more motivated to do everything possible to 262 
control their cat’s diabetes, better treatment outcomes might be expected in that group. Nevertheless, owners 263 
in both groups were prepared to follow the other aspects of the clinical trial, which included regular visits to the 264 
research clinic, indicating that even the owners in the non-HBGM group were committed to the care of their 265 
diabetic cat. Additionally, assigning owners to one of the two groups, and thus forcing some of them to accept 266 
HBGM, would not be feasible or ethical. On the basis of direct comparison of QoL and glycaemic parameters, 267 
the two groups were very similar at enrolment, further strengthening the validity of the comparisons drawn.  268 
We used a questionnaire to assess the cat owners’ experiences with the HBGM. Although closed-ended 269 
questions offering fixed answer(s) were used, the option “other” was included in most of the questions, to 270 
enable owners to provide additional free text information. Using open-ended questions might have been more 271 
suitable to assess the owners’ opinions on some issues (e.g. advantages/disadvantages of HBGM) without 272 
introducing bias. However, using open-ended questions is also associated with higher risk of larger item non-273 
response or invalid answers, resulting in missing data.18 Therefore, we compromised by including the option 274 
“other”. 275 
The maximal BG at month 6 was significantly lower in the HBGM group compared to the non-HBGM group. 276 
Additionally, in the HBGM-group, all glycaemic control parameters (except for minimal BG at months 3 and 6) 277 
decreased significantly compared to enrolment values. In contrast, in the non-HBGM group, improvement in 278 
only 2 glycaemic control parameters (maximal BG at month 1 and average BG at month 6) was identified, and 279 
there was no consistent pattern for the remaining parameters. Nevertheless, it should also be emphasised 280 
that when performing a direct comparison between cats in the HBGM- and non-HBGM group, a statistical 281 
significant difference was not shown at any time point during the study. Superior glycaemic control has been 282 
linked with higher remission rates.19 Also, HBGM was an essential part of management in studies reporting 283 
the highest remission rates.5,6 Interestingly, 9/28 (32%) cats in the HBGM group underwent diabetic remission, 284 
but this occurred in only 1/10 (10%) cats in the non-HBGM group. However, the difference between groups in 285 
remission rates was not statistically significant. Large randomised prospective studies are recommended to 286 
further investigate the impact of HBGM on remission rates. 287 
Finally, random assignment of owners and cats to equally-sized HBGM- and non-HBGM groups might have 288 
yielded superior results in this respect. Given the importance of HBGM suggested in previous studies,5,6 our 289 
research group, guided by our ethical committee, considered that it would be inappropriate to not actively offer 290 
HBGM to owners as part of best clinical practice. Conversely, forcing owners, who could not or did not want to 291 
perform HBGM to enrol in the HBGM group would not be feasible or ethical either. Although this approach 292 
might have introduced selection bias into the study, this situation is more likely to reflect the “real-life” 293 
circumstances when, ideally, all owners should be able to make an informed choice about the protocol they 294 
use to manage their cat’s diabetes.  295 
 296 
Conclusions 297 
Most (n=28/38; 74%) owners of diabetic cats were able to perform HBGM and the majority (n=17/19; 89%) 298 
considered it to be (mostly) straightforward. Overall QoL evaluated by the validated psychometric tool 299 
DIAQoL-pet improved significantly in cats/ owners choosing to perform HBGM. Specifically of interest was an 300 
owner-reported decrease in worry about the diabetes and particularly hypoglycaemia in the HBGM group, 301 
which did not occur in the non-HBGM group. This study adds to the body of peer-reviewed evidence that 302 
suggests HBGM is a practical monitoring tool for many owners of diabetic cats and suggests it is associated 303 
with a positive impact on QoL in both the diabetic cat and the owner. Further studies are warranted to assess 304 
its possible positive impact on glycaemic control. 305 
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  374 
Table 1. The validated Diabetic Clinical Score (DCS) used to grade the severity of diabetes-associated clinical 375 
signs in participating cats  376 
Clinical Sign Being Scored Severity 
Assigned 
Score 
Unintended weight loss over the past 2 
months 
(Assessed using bodyweight records or  
measurements) 
None, or weight gain 
Mild (<5% loss) 
Moderate (5-10% loss) 
Severe (>10% loss) 
0 
1 
2 
3 
Increased drinking and/or urination 
(Assessed by questioning owner) 
None 
Mild – some increase noted 
Moderate – increased filling of water bowl 
Severe – constantly seen to drink 
0 
1 
2 
3 
Increased appetite 
(Assessed by questioning owner) 
Normal or decreased appetite 
Mild – finishes food eagerly 
Moderate – finishes food eagerly and begs 
for more 
Severe – obsessed with food 
0 
1 
2 
3 
Decreased activity/ attitude 
(Assessed by questioning owner) 
Normal or increased activity 
Mild – slightly less active 
Moderate – certainly less active 
Severe – mainly lying around 
0 
1 
2 
3 
 Total score /12 
 377 
  378 
Table 2. Overview of questions (items) of the DIAQoL-pet survey3 pertinent with regards to home blood 379 
glucose monitoring (HBGM). Each item was scored according to frequency at which it impacted on owner’s 380 
and pets’ lives (all the time [3], often [2], occasionally [1], never [0]) and how important the item was in the 381 
individual owner’s and pet’s lives (very important [4], important [3], moderately important [2], low importance 382 
[1], not at all important [0]). Item-weighted impact score (IWIS) was calculated for each item by multiplying 383 
frequency and importance ratings for each question. 384 
Abbreviation Question (item) 
More control Do you ever feel you want to take more control of the diabetes on your own, 
without the help of vets and other people? 
Hypoglycaemia Does your pet ever show signs of a low blood sugar? (eg, wobbliness, collapse) 
Worry hypo Do you ever feel worried about your pet suffering from an episode of low blood 
glucose? 
Costs Do you ever worry about how much money your pet’s diabetes costs you and 
your family? 
Worry Do you ever worry about your pet’s diabetes? 
Restrict your 
activities 
Do you ever find the diabetes of your pet restricts or limits what you are doing or 
what you want to do, like going on holidays, away on weekends, away for the 
day/night, working? 
Social life Do you ever find you need to fit your pet’s diabetes into your social life? (eg, 
carrying needles, food, insulin, providing food on time) 
Working life Do you ever find you need to fit your pet’s diabetes into your working life? (eg, 
having to make special arrangements when you need to work late or need to 
start working earlier) 
Special bond Do you feel you have a more special bond with your pet now that you are 
managing his/her diabetes? 
  385 
Table 3. Comparison of the demographic data, DIAQoL-pet score (quality of life tool) and parameters of 386 
glycaemic control (DCS – diabetic clinical score; serum fructosamine; average blood glucose based on blood 387 
glucose curve) between the HBGM (home blood glucose monitoring)- and non-HBGM group at enrolment, 388 
months 1, 3 and 6. 389 
Parameter HBGM group Non-HBGM group p-value 
Number of cats 28 10  
Age (years) (median, range) 12.05 (4-17.2) 9.5 (7-15.5) 0.076 
Age (months) (median, range) 144.7  
(48.4-206.8) 
113.3  
(84.1-185.4) 
0.085 
Breed 
- Domestic Shorthair+Longhair 
- Other breed 
 
25 
 
3 
 
9 
 
1 
1.00 
Gender 
- female spayed 
- male neutered  
 
15 
13 
 
1 
9 
0.025 
BW (kg) (median, range) 4.4 (2.8-8.3) 5.1 (3-6.9) 0.226 
BCS (median, range) 5 (1-8) 5 (3-8) 0.723 
% BF (median, range) 22.8 (2.11-42.5) 21.6 (16.6-32.4) 0.921 
fPLI (ug/L) (median, range) 3.55 (0.5-58.0) 3.8 (0.5-50) 0.715 
Time on insulin prior to enrolment 
(days) 
59 (36-150) 60.5 (44-108) 0.947 
Insulin dose prior to enrolment (U/cat) 2 (1-5) 2.5 (1-6) 0.893 
Insulin dose prior to enrolment (U/kg 
BW) 
0.51 (0.22-1.32) 0.54 (0.24-1.16) 0.691 
Insulin type subsequently used 14 ProZinc/  
14 Glargine 
5 ProZinc /  
5 Glargine 
1.00 
DIAQoL-pet month 0  
(median, range) 
-1.52  
(-4.45 - -0.31) 
-1.31  
(-5.34 - -0.1) 
0.390 
DIAQoL-pet month 1  
(median, range) 
-1.12  
(-3.69 - +0.28) 
-1.21  
(-3.59 - -0.3) 
0.940 
DIAQoL-pet month 3  
(median, range) 
-0.95  
(-4.83 - +0.38) 
-0.76  
(-1.59 - -0.3) 
0.603 
DIAQoL-pet month 6  
(median, range) 
-0.45  
(-3.14 - +0.14) 
-0.9  
(-2.28 - -0.3) 
0.352 
Serum fructosamine month 0 (umol/L) 
(median, range) 
476.5 (59-715) 431.5 (168-715) 0.703 
Serum fructosamine month 1 (umol/L) 
(median, range) 
380 (232-572) 398.5(233-575) 0.473 
Serum fructosamine month 3 (umol/L) 
(median, range) 
302 (215-606) 349 (241-560) 0.406 
Serum fructosamine month 6 (umol/L) 
(median, range) 
307 (215-636) 351 (248-561) 0.429 
DCS month 0 (median, range) 3.5 (0-11) 3.5 (0-9) 0.651 
DCS month 1 (median, range) 1 (0-5) 1.5 (0-5) 0.750 
DCS month 3 (median, range) 0 (0-6) 1 (0-4) 0.118 
DCS month 6 (median, range) 0 (0-6) 1 (0-2) 0.417 
Average BG month 0 (mmol/L)  
(median, range) 
14.2  
(7.9-21.7) 
12.9  
(7.7-22.2) 
0.829 
Average BG month 1 (mmol/L)  
(median, range) 
10.6  
(4.1-21.5) 
10.5  
(4-19.2) 
0.572 
Average BG month 3 (mmol/L)  
(median, range) 
10.85  
(4.1-21.4) 
14.35  
(7.6-19.7) 
0.234 
Average BG month 6 (mmol/L)  
(median, range) 
9.95  
(3.4-19.9) 
13.75  
(7.7-19.3) 
0.146 
Remission rate (remission/all) 9/28 1/10 0.236 
Time to remission 70 (40-130) 45 (n/a) n/a 
BW – body weight; BCS – body condition score (1-9/9)15; % BF – percentage of body fat16; BG – blood 390 
glucose; n/a – not applicable 391 
Table 4. Comparison of DIAQoL-pet (quality-of-life tool), including specific questions (see below), between 392 
enrolment and months 1, 3 and 6 within the HBGM group. 393 
Parameter Enrolment 
(month 0) 
Month 1 Month 3 Month 6 
DIAQoL-pet 
(median, range) 
-1.52 
(-4.45 - -0.31) 
-1.12  
(-3.69 - +0.28) 
-0.95  
(-4.83 - +0.38) 
-0.45  
(-3.14 - +0.14) 
“owner wanting 
more control” 
(median, range) 
0.00  
(-12.00 – 0.00) 
0.00  
(-8.00 – 0.00) 
0.00  
(-6.00 – 0.00) 
0.00  
(-4.00 – 0.00) 
“hypo”  
(median, range) 
0.00  
(-4.00 – 0.00) 
0.00  
(-3.00 – 0.00) 
0.00  
(-8.00 – 0.00) 
0.00  
(-4.00 – 0.00) 
“worry hypo”  
(median, range) 
-3.00  
(-8.00 – 0.00) 
-3.00  
(-9.00 – 0.00) 
-1.00  
(-12.00 – 0.00) 
0.00  
(-8.00 – 0.00) 
“costs”  
(median, range) 
-4.00  
(-12.00 – 0.00) 
-2.00  
(-12.00 – 0.00) 
-1.00   
(-12.00 – 0.00) 
0.00  
(-12.00 – 0.00) 
“worry”  
(median, range) 
-4.00   
(-12.00 - -1.00) 
-2.00  
(-12.00 – 0.00) 
-3.00  
(-12.00 – 0.00) 
-2.00  
(-12.00 – 0.00) 
“restrict your 
activities” (median, 
range) 
-3.00  
(-12.00 – 0.00) 
-2.00  
(-12.00 – 0.00) 
-2.00  
(-12.00 – 0.00) 
0.00  
(-9.00 – 0.00) 
“social life” 
(median, range) 
-3.00  
(-12.00 – 0.00) 
-2.00  
(-12.00 – 0.00) 
-1.00  
(-12.00 – 0.00) 
0.00  
(-9.00 – 0.00) 
“working life”  
(median, range) 
-2.00  
(-12.00 – 0.00) 
0.00  
(-12.00 – 0.00) 
-2.00  
(-12.00 – 0.00) 
0.00  
(-12.00 – 0.00) 
“special bond”  
(median, range) 
2.00  
(0.00 – 12.00) 
2.00  
(0.00 – 12.00) 
1.00  
(0.00 – 12.00) 
2.00  
(0.00 – 12.00) 
 The value is significantly different from enrolment (month 0) at a level of significance p<0.05 394 
 The value is significantly different from enrolment (month 0) at a level of significance p<0.01 395 
 The value is significantly different from enrolment (month 0) at a level of significance p<0.001 396 
 The value is significantly different from enrolment (month 0) at a level of significance p<0.0001 397 
 398 
Table 5. Comparison of parameters of glycaemic control at different time points within the HBGM group. 399 
Parameter Enrolment  
(month 0) 
Month 1 Month 3 Month 6 
DCS (median, range) 3.5  
(0-11) 
1  
(0-5) 
0  
(0-6) 
0  
(0-6) 
Serum fructosamine 
(umol/L) (median, range) 
476.5  
(59-715) 
380  
(232-572) 
302  
(215-606) 
307  
(215-636) 
Insulin dose (U/cat) 
(median, range) 
2  
(1-5) 
2  
(0.25-5.5) 
2  
(0-5) 
1.5  
(0-6.5) 
Insulin dose (U/kg BW) 
(median, range) 
0.51  
(0.22-1.32) 
0.45  
(0.06-1.36) 
0.41  
(0-1.08) 
0.32  
(0-1.65) 
Average BG (mmol/L) 
(median, range) 
14.2  
(7.9-21.7) 
10.6  
(4.1-21.5) 
10.85  
(4.1-21.4) 
9.95  
(3.4-19.9) 
Average pre-insulin BG 
(mmol/L)  
(median, range) 
18.2  
(8.3-23.3) 
11.75  
(5.5-20.6) 
11.45  
(3.6-22.2) 
13.1  
(6.7-19.9) 
Minimal BG (mmol/L) 
(median, range) 
6.55  
(2.2-18.4) 
3.5  
(2.2-18.4) 
5.7  
(2.2-17.1) 
4.9  
(2.2-12.8) 
Maximal BG (mmol/L) 
(median, range) 
22.2  
(13.2-22.2) 
20.2  
(8.9-22.2) 
19.5  
(6.3-22.2) 
14.9  
(5.4-22.2) 
DCS – diabetic clinical; BG – blood glucose 400 
 The value is significantly different from enrolment (month 0) at a level of significance p<0.05 401 
 The value is significantly different from enrolment (month 0) at a level of significance p<0.01 402 
 The value is significantly different from enrolment (month 0) at a level of significance p<0.001 403 
 The value is significantly different from enrolment (month 0) at a level of significance p<0.0001 404 
  405 
Table 6. Summary of advantages and disadvantages of home blood glucose monitoring (HBGM) as well as 406 
description of the technique and difficulties encountered during HMBG. Number and percentage of 407 
respondents (of 19 returned questionnaires) are given in brackets after the item. 408 
Advantages of HMBG: 
- not having to take their cat to the veterinarian or leave the cat at the practice (n=16; 84%) 
- owner feeling to have more control over their cat’s diabetes (n=13; 68%) 
- owner feeling their cat’s diabetes is better controlled since performing HMBG (n=12; 63%) 
- lower costs compared to glucose curves at veterinary practice (n=12; 63%) 
- less stressful compared to glucose curves at veterinary practice (n=11; 58%) 
Disadvantages of HMBG: 
- no disadvantages (n=6; 32%) 
- HMBG is time consuming (n=7; 37%) 
- cat seems uncomfortable during the procedure (n=6; 32%) 
- owner feeling he/she is hurting the cat (n=6; 32%) 
Sampling site: 
- outer pinna (n=14; 74%), outer + inner pinna (n=1; 5%) 
- paw pad of the front limb (n=1; 5%), paw pad of the hind limb (n=1; 5%), paw pad of the 
front and hind limb (n=2; 11%) 
Tools used to obtain blood samples: 
- lancet (n=16; 84%), hypodermic needle (n=1; 5%), insulin needle (n=1; 5%), needle from 
the lancet (n=1; 5%) 
Additional procedures to enhance blood sampling: 
- massage the ear before puncturing it (n=12; 63%) 
- apply vaseline (n=7; 37%) 
- apply anaesthetic cream (e.g. EMLA) (n=5; 26%) 
- clipping the ear for better visualisation of the marginal ear vein (n=2; 11%) 
- using a small torch for better visualisation of the marginal ear vein (n=1; 5%) 
Need for other person to assist during HBGM: 
- always (n=7; 37%), sometimes (n=5; 26%), never (n=7; 37%) 
Recording of blood glucose readings: 
- using a diary (not digital) (n=13; 68%) 
- creating tables/graphs using a computer programme/software, e.g. Microsoft Excel (n=3; 
16%) 
- using a chart supplied with the glucometer (n=2; 11%) 
- using an App for human diabetics or pets (n=1; 5%) 
Difficulties encountered during HMBG: 
- need for more than 1 puncture due to technical difficulties (n=17; 89%) 
- obtaining a too small blood drop (n=8; 42%) 
- difficulties using the glucometer (n=8; 42%) 
- cat resisting the sampling (n=6; 32%) 
- bruising (n=1; 5%) or formation of scar tissue (n=1; 5%) at the puncture site  
How the difficulties with HMBG could be resolved: 
- practising the technique and the use of the glucometer (n=13; 68%) 
- advice given at the re-examination at our clinic or local veterinarian (n=4; 21%) 
 409 
  410 
Figure 1. DIAQoL-pet score (quality-of-life tool) in the home blood glucose monitoring (HBGM) and non-411 
HBGM groups over the 6 month study period. Higher scores are suggestive of better quality of life. 412 
Circles/squares and error bars represent median and range. Significantly different values (P <0.05) are 413 
marked with an asterisk. 414 
 415 
  416 
Figure 2. Average blood glucose (obtained from 24 h blood glucose curves) in the home blood glucose 417 
monitoring (HBGM) and non-HBGM groups over the 6 month study period. Circles/squares and error bars 418 
represent median and range. Significantly different values (P <0.05) are marked with an asterisk. Average 419 
blood glucose was significantly lower at months 1, 3 and 6 compared with baseline in the HBGM group but not 420 
in the non-HBGM group. There were no significant differences in average blood glucose between the groups 421 
at any time point. 422 
 423 
  424 
Figure 3. Serum fructosamine concentration in the home blood glucose monitoring (HBGM) and non-HBGM 425 
group over the study period. Circles/squares and error bars represent median and range. Significantly 426 
different values (P <0.05) are marked with an asterisk. Serum fructosamine concentrations were significantly 427 
lower at months 1, 3 and 6 compared with baseline in the HBGM group but not in the non-HBGM group. 428 
There were no significant differences in serum fructosamine concentrations between the groups at any time 429 
point 430 
 431 
